Fosinopril could reduce cardiovascular events in end-stage renal disease
This article has no abstract so we have provided the first paragraph of the full text.
Cardiovascular events (CVEs) cause substantial mortality and morbidity in patients with end-stage renal disease (ESRD). Angiotensin-converting-enzyme inhibitors, such as fosinopril, have proved to be both well-tolerated and efficacious for the prevention of CVEs in a range of clinical trials, yet these trials have tended to exclude patients with ESRD. This double-blind, multicenter, randomized controlled study assessed the safety and efficacy of fosinopril in 397 ESRD patients who were on hemodialysis and who had left ventricular hypertrophy.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
